SHANGHAI, June 27, 2023 /PRNewswire/ -- Aurisco Pharmaceutical has good reasons to celebrate. On its 25th anniversary, the high-tech pharmaceutical company dedicated to innovation has received its first Marketing Authorization Approval in China for AUXITON®, the oral finished dosage form of Dydrogesterone, from China's Health Authority, the NMPA. Aurisco is the only company holding both an active USDMF and a valid CEP – the Certificate of compliance with the European Pharmacopoeia, issued by the EDQM for the drug substance.
Oral Dydrogesterone Plus Vaginal Progesterone Can Reduce Miscarriage Rate
Mankind Pharma launches drug for treatment of infertility in India